PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23701022-8	2013	Our data suggest that concomitant tenofovir (TDF) use may be a risk factor for the development of hypophosphatemia in HIV/HCV-coinfected patients treated with IFN/RBV.	Tenofovir	34-43	interferon alpha 1	Homo sapiens	159-166	
33535672-6	2021	Here, we reviewed previous reports regarding the effects of combination therapy of entecavir or tenofovir with Peg-IFNalpha, focusing on long-term reduction in HBsAg levels.	Tenofovir	96-105	interferon alpha 1	Homo sapiens	115-123	
33185325-3	2021	We analyzed data of a prospective treatment trial where 120 HDV-RNA positive patients were randomized to receive PEG-IFNalpha-2a plus tenofovir-disoproxil-fumarate (PEG-IFNalpha/TDF, n=59) or placebo (PEG-IFNalpha/PBO; n=61) for 96 weeks.	Tenofovir	134-163	interferon alpha 1	Homo sapiens	169-177